NO20060080L - Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer - Google Patents

Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer

Info

Publication number: NO20060080L
Authority: NO; Norway
Prior art keywords: liver; dition; pyrrole; derivatives; receptor modulators
Prior art date: 2003-07-11

Application number

NO20060080A

Other languages

English (en)

Norwegian (no)

Inventor

Patrik Holm

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-11

Filing date

2006-01-05

Publication date

2006-02-08

2006-01-05 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2006-02-08 Publication of NO20060080L publication Critical patent/NO20060080L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)

NO20060080A 2003-07-11 2006-01-05 Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer NO20060080L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0316237.7A GB0316237D0 (en)	2003-07-11	2003-07-11	Therapeutic agents
PCT/SE2004/001115 WO2005005416A1 (en)	2003-07-11	2004-07-08	Pyrrole-2, 5-dithione derivatives as liver x receptor modulators

Publications (1)

Publication Number	Publication Date
NO20060080L true NO20060080L (no)	2006-02-08

Family

ID=27741986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20060080A NO20060080L (no)	2003-07-11	2006-01-05	Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer

Country Status (26)

Country	Link
US (1)	US20060189663A1 (de)
EP (1)	EP1646625B1 (de)
JP (1)	JP2007521313A (de)
KR (1)	KR20060034284A (de)
CN (1)	CN100478340C (de)
AR (1)	AR045720A1 (de)
AT (1)	ATE399776T1 (de)
AU (1)	AU2004256000B2 (de)
BR (1)	BRPI0412479A (de)
CA (1)	CA2532068A1 (de)
CO (1)	CO5640134A2 (de)
DE (1)	DE602004014772D1 (de)
ES (1)	ES2308205T3 (de)
GB (1)	GB0316237D0 (de)
HK (1)	HK1088318A1 (de)
IL (1)	IL172759A0 (de)
IS (1)	IS8291A (de)
MX (1)	MXPA06000447A (de)
NO (1)	NO20060080L (de)
RU (1)	RU2006102129A (de)
SA (1)	SA04250203B1 (de)
TW (1)	TW200507836A (de)
UA (1)	UA82108C2 (de)
UY (1)	UY28407A1 (de)
WO (1)	WO2005005416A1 (de)
ZA (1)	ZA200600229B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0500058D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 5
SE0500055D0 (sv)	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 3
EP1838686A4 (de)	2005-01-10	2010-02-24	Astrazeneca Ab	Derivate von isothiazol-3(2h)-one-1,1-dioxiden als liver-x-rezeptormodulatoren
ES2438739T3 (es) *	2005-06-28	2014-01-20	Daiichi Sankyo Company, Limited	Procedimiento de prueba de ligando LXR
MX2009001875A (es)	2006-08-21	2009-03-02	Genentech Inc	Compuestos de aza-benzotiofenilo y metodos de uso de los mismos.
US20100056444A1 (en)	2006-10-12	2010-03-04	Sven Martin Jacobson	Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors
US10004703B2 (en)	2006-10-12	2018-06-26	Biogen Chesapeake Llc	Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
WO2008103818A1 (en) *	2007-02-21	2008-08-28	University Of Louisville Research Foundation	Therapeutic cotinine compositions
PL2868315T3 (pl)	2007-12-04	2018-06-29	Biogen Chesapeake Llc	Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty
US20110034560A1 (en)	2008-01-29	2011-02-10	Sven Jacobson	Liquid formulations of compounds active at sulfonylurea receptors
WO2010003025A1 (en)	2008-07-01	2010-01-07	Genentech, Inc.	Bicyclic heterocycles as mek kinase inhibitors
KR20110028376A (ko)	2008-07-01	2011-03-17	제넨테크, 인크.	Ｍｅｋ 키나제 억제제로서의 이소인돌론 유도체 및 사용 방법
WO2012033353A2 (ko)	2010-09-07	2012-03-15	서울대학교 산학협력단	세스터터핀 화합물 및 이들 물질의 용도
AU2015204572B2 (en)	2014-01-10	2020-07-30	Inspirna, Inc.	LXR agonists and uses thereof
AU2017207291B2 (en)	2016-01-11	2023-06-15	The Rockefeller University	Methods for the treatment of myeloid derived suppressor cells related disorders
JP2021504315A (ja)	2017-11-21	2021-02-15	ルジェニクス，インコーポレーテッド	多形及びその使用
KR200492570Y1 (ko)	2018-12-04	2020-11-05	박규환	조립식 계단장치를 위한 발판
EP4073025B1 (de)	2019-12-13	2024-03-27	Inspirna, Inc.	Metallsalze und verwendungen davon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE284387T1 (de) *	1998-10-08	2004-12-15	Smithkline Beecham Plc	3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
WO2001003705A1 (en) *	1999-07-08	2001-01-18	Tularik Inc.	Compositions and methods for raising hdl cholesterol levels

2003
- 2003-07-11 GB GBGB0316237.7A patent/GB0316237D0/en not_active Ceased
2004
- 2004-06-29 TW TW093119119A patent/TW200507836A/zh unknown
- 2004-07-05 SA SA4250203A patent/SA04250203B1/ar unknown
- 2004-07-08 JP JP2006520139A patent/JP2007521313A/ja not_active Withdrawn
- 2004-07-08 MX MXPA06000447A patent/MXPA06000447A/es not_active Application Discontinuation
- 2004-07-08 BR BRPI0412479-0A patent/BRPI0412479A/pt not_active IP Right Cessation
- 2004-07-08 KR KR1020067000616A patent/KR20060034284A/ko not_active Application Discontinuation
- 2004-07-08 CA CA002532068A patent/CA2532068A1/en not_active Abandoned
- 2004-07-08 AR ARP040102418A patent/AR045720A1/es not_active Application Discontinuation
- 2004-07-08 WO PCT/SE2004/001115 patent/WO2005005416A1/en active IP Right Grant
- 2004-07-08 AU AU2004256000A patent/AU2004256000B2/en not_active Ceased
- 2004-07-08 ES ES04749151T patent/ES2308205T3/es not_active Expired - Lifetime
- 2004-07-08 CN CNB2004800197194A patent/CN100478340C/zh not_active Expired - Fee Related
- 2004-07-08 DE DE602004014772T patent/DE602004014772D1/de not_active Expired - Fee Related
- 2004-07-08 RU RU2006102129/04A patent/RU2006102129A/ru not_active Application Discontinuation
- 2004-07-08 US US10/563,676 patent/US20060189663A1/en not_active Abandoned
- 2004-07-08 EP EP04749151A patent/EP1646625B1/de not_active Expired - Lifetime
- 2004-07-08 AT AT04749151T patent/ATE399776T1/de not_active IP Right Cessation
- 2004-07-09 UY UY28407A patent/UY28407A1/es unknown
- 2004-08-07 UA UAA200600270A patent/UA82108C2/uk unknown
2005
- 2005-12-22 IL IL172759A patent/IL172759A0/en unknown
2006
- 2006-01-05 NO NO20060080A patent/NO20060080L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600229A patent/ZA200600229B/xx unknown
- 2006-01-20 CO CO06005238A patent/CO5640134A2/es not_active Application Discontinuation
- 2006-02-09 IS IS8291A patent/IS8291A/is unknown
- 2006-08-07 HK HK06108722.2A patent/HK1088318A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN100478340C (zh)	2009-04-15
UA82108C2 (uk)	2008-03-11
HK1088318A1 (en)	2006-11-03
US20060189663A1 (en)	2006-08-24
DE602004014772D1 (de)	2008-08-14
JP2007521313A (ja)	2007-08-02
IL172759A0 (en)	2006-04-10
CA2532068A1 (en)	2005-01-20
ATE399776T1 (de)	2008-07-15
WO2005005416A1 (en)	2005-01-20
SA04250203B1 (ar)	2008-02-25
AU2004256000B2 (en)	2007-07-26
UY28407A1 (es)	2005-02-28
ES2308205T3 (es)	2008-12-01
CO5640134A2 (es)	2006-05-31
EP1646625B1 (de)	2008-07-02
CN1820003A (zh)	2006-08-16
ZA200600229B (en)	2007-04-25
GB0316237D0 (en)	2003-08-13
BRPI0412479A (pt)	2006-09-19
AR045720A1 (es)	2005-11-09
RU2006102129A (ru)	2006-08-27
IS8291A (is)	2006-02-09
TW200507836A (en)	2005-03-01
KR20060034284A (ko)	2006-04-21
EP1646625A1 (de)	2006-04-19
AU2004256000A1 (en)	2005-01-20
MXPA06000447A (es)	2006-04-07

Publication	Publication Date	Title
NO20060080L (no)	2006-02-08	Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer
NO20073250L (no)	2007-07-19	Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.
NO20060081L (no)	2006-02-08	Pyrrol-2,5-dionderivater som lever X reseptormodulatorer
CN104302634B (zh)	2017-02-08	用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
ES2284740T3 (es)	2007-11-16	Carboxilato de terfenadina y el tratamiento de la irritacion cutanea.
WO2007050726A3 (en)	2007-08-30	Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
NO20055892L (no)	2006-01-06	Karboksylsyrederivater
NO20073248L (no)	2007-10-01	Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer
WO2007082808A3 (en)	2007-09-13	Thiazoles as 11 beta-hsd1 inhibitors
WO2009009501A3 (en)	2009-04-02	Non-basic melanin concentrating hormone receptor-1 antagonists and methods
CN102093246B (zh)	2014-10-29	酯类化合物、其制备方法和应用
CN102137858A (zh)	2011-07-27	5-脂氧合酶-活化蛋白抑制剂
NO20065501L (no)	2007-01-30	Lxr reseptor modulstorer.
Al-Masri et al.	2024	Antidiabetic effect of flavonoid from Rumex vesicarius on alloxan induced diabetes in male albino Wistar rats and its validation through in silico molecular docking and dynamic simulation studies
Mouihate et al.	2006	Oxyresveratrol dampens neuroimmune responses in vivo: a selective effect on TNF-α
SE0500056D0 (sv)	2005-01-10	Therapeutic agents 4
EP2412705B1 (de)	2014-05-07	Neues therapeutikum für kognitive beeinträchtigung
SE0500058D0 (sv)	2005-01-10	Therapeutic agents 5
CN109906222A (zh)	2019-06-18	减少p-tau并且改善认知的变构促肾上腺皮质激素释放因子受体1(crfr1)拮抗剂
Ma et al.	2016	Straightforward and effective synthesis of γ-aminobutyric acid transporter subtype 2-selective acyl-substituted azaspiro [4.5] decanes
AU646240B2 (en)	1994-02-17	4,4'-{9H-fluoren-9-ylidenebis(methylene)}-bispyrimidine for treating neurological disorders
Wang et al.	2024	Drug discovery targeting thyroid hormone receptor β (THRβ) for the treatment of liver diseases and other medical indications
CN103040779A (zh)	2013-04-17	用于神经系统疾病的口服固体药物组合物
CN104523712B (zh)	2018-08-24	一种盐酸吡格列酮格列美脲片剂组合物
CN108368095A (zh)	2018-08-03	作为sap消耗剂的d-脯氨酸衍生物

Legal Events

Date	Code	Title	Description
2009-02-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application